loading page

Quercetin and Hydroxytyrosol as modulators of hepatic steatosis: a NAFLD-on-a-chip study.
  • +4
  • Manuele Gori,
  • Sara Giannitelli,
  • Andrea Zancla,
  • Pamela Mozetic,
  • Marcella Trombetta,
  • Nicolò Merendino,
  • Alberto Rainer
Manuele Gori
Universita Campus Bio-Medico di Roma

Corresponding Author:[email protected]

Author Profile
Sara Giannitelli
Università Campus Bio-Medico di Roma Facoltà di Ingegneria
Author Profile
Andrea Zancla
Università degli Studi Roma Tre
Author Profile
Pamela Mozetic
University Hospital “St. Anne”
Author Profile
Marcella Trombetta
Universita Campus Bio-Medico di Roma
Author Profile
Nicolò Merendino
Università degli Studi della Tuscia
Author Profile
Alberto Rainer
Universita Campus Bio-Medico di Roma
Author Profile


Organs-on-chip are increasingly catching on as a promising and valuable alternative to animal models, in line with the 3Rs initiative, to create 3D tissue microenvironments in which cells behave physiologically and pathologically at unparalleled precision and complexity. Indeed, these platforms offer new opportunities to model human diseases and test the potential therapeutic effect of different drugs as well as their limitations, overtaking the limited predictive accuracy of conventional 2D culture systems. Here, we present a liver-on-a-chip model to investigate the effects of two naturally occurring polyphenols, namely Quercetin and Hydroxytyrosol, on non-alcoholic fatty liver disease (NAFLD) using a method of high-content analysis. NAFLD is currently the most common form of chronic liver disease, whose complex pathogenesis is far from being clear. Besides, no definitive treatment has been established for NAFLD so far. In our experiments, we observed that both polyphenols seem to restrain the progression of the free fatty acid-induced hepatocellular steatosis, showing a cytoprotective effect due to their antioxidant properties. In conclusion, the resulting insights of the present work could guide novel strategies to contrast the onset and progression of NAFLD.
28 Jan 2020Submitted to Biotechnology and Bioengineering
28 Jan 2020Submission Checks Completed
28 Jan 2020Assigned to Editor
16 Feb 2020Reviewer(s) Assigned
18 Jul 2020Review(s) Completed, Editorial Evaluation Pending
18 Jul 2020Editorial Decision: Revise Minor
16 Aug 20201st Revision Received
17 Aug 2020Submission Checks Completed
17 Aug 2020Assigned to Editor
01 Sep 2020Reviewer(s) Assigned
02 Sep 2020Review(s) Completed, Editorial Evaluation Pending
02 Sep 2020Editorial Decision: Accept